Sign In
Buy BCAB
$3.29
-0.0900 (-2.66%)
At Close: Jul 31, 2026
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
04:05pm, Tuesday, 06'th May 2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera
BioAtla to Participate in the Citizens Life Sciences Conference
08:00am, Wednesday, 30'th Apr 2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
08:00am, Tuesday, 29'th Apr 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
10:05am, Wednesday, 23'rd Apr 2025
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
06:18pm, Thursday, 27'th Mar 2025
BioAtla, Inc. (NASDAQ:BCAB ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive O
BioAtla Cuts 30% of Jobs in Restructuring Effort
05:05pm, Thursday, 27'th Mar 2025
The San Diego biopharmaceutical company, which focuses on treating solid tumor cancers, said Thursday its workforce reduction is part of an effort to extend its runway beyond key clinical readouts in
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
04:05pm, Thursday, 27'th Mar 2025
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
08:00am, Thursday, 20'th Mar 2025
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
08:00am, Wednesday, 19'th Mar 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know
01:10pm, Thursday, 02'nd Jan 2025
BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
09:00am, Friday, 20'th Dec 2024
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionall
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
08:00am, Tuesday, 10'th Dec 2024
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
08:53am, Saturday, 09'th Nov 2024
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive
